Related Experiment Video

Updated: Feb 2, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.0K

Impact of cardiac resynchronization therapy on circulating IL-17 producing cells in patients with advanced heart

Sílvia Martins1,2, Tiago Carvalheiro3, Paula Laranjeira2,4

  • 1CICS-UBI - Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior, Covilhã, Portugal.

Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing
|November 29, 2018
PubMed

Insights

Cardiac resynchronization therapy (CRT) reduced the frequency of IL-17-producing T cells in chronic heart failure (CHF) patients, particularly in responders. This suggests CRT may suppress the inflammatory response associated with CHF.

Area of Science:

  • Immunology
  • Cardiology
  • Molecular Biology

Background:

  • Interleukin-17 (IL-17)-producing T cells are linked to poor prognosis in chronic heart failure (CHF).
  • Understanding the role of these cells and the impact of treatments like cardiac resynchronization therapy (CRT) is crucial for managing CHF.

Purpose of the Study:

  • To investigate the effect of CRT on the frequency and function of T helper 17 (Th17) and T cytotoxic 17 (Tc17) cells.
  • To assess changes in IL-17 messenger RNA (mRNA) expression following CRT in CHF patients.

Main Methods:

  • Flow cytometry was used to quantify circulating Th17 and Tc17 cells in 28 CHF patients before (T0) and 6 months after (T6) CRT, and in 15 healthy controls (HC).
  • Real-time polymerase chain reaction (PCR) was employed to measure IL-17A mRNA expression.

Main Results:

  • Tc17 cell frequency decreased significantly in CHF patients after CRT (T0 vs. T6, P < 0.05), returning to levels similar to HC.
  • IL-17 mRNA expression was detected in a subset of responders at T0 and T6, but increased in non-responders at T6.
  • No significant changes in Th17 cell frequency were observed across groups.

Conclusions:

  • CRT appears to suppress the inflammatory response mediated by IL-17-producing cells in CHF patients.
  • The suppression is particularly evident in patients who respond to CRT.
Abstract

Keywords:
Cardiac resynchronization therapyChronic heart failureCytokinesTc17 cellTh17 cell

More Related Videos

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice14:26

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice

Published on: April 7, 2014

16.2K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.2K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
339
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
933
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
888
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
968
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
316